Interview with Deepak Khanna, Senior Vice President and Managing Director UK,…
You were previously managing the Merck/Schering-Plough joint venture in the US, and arrived in the UK 2 years ago. What did you set out for yourself as head of the…
Address: Merck Sharp & Dohme Limited, Hertford Road, Hoddesdon, Hertfordshire, EN11 9BU, United Kingdom
Tel: +44 (0) 1992 467272
Merck Sharp & Dohme Limited (MSD) is the UK subsidiary of Merck & Co., Inc., of Whitehouse Station, New Jersey, USA, a leading research-based pharmaceutical company that discovers, develops, manufactures and markets a wide range of innovative pharmaceutical products to improve human health.
MSD has committed substantial investment to research and manufacturing in the UK because of the unrivalled scientific excellence and skills base available here. It has two sites in the UK: headquarters and pharmaceutical research and development laboratories in Hoddesdon, Hertfordshire; and manufacturing at Cramlington in Northumberland.
x MSD employs approximately 1,400 people in the UK
x MSD’s UK headquarters are located in Hoddesdon, Hertfordshire, where the company’s sales and marketing, medical services, market research and administration functions are situated
x Pharmaceutical research and development is also located at Hoddesdon. Recent investment has established Hoddesdon as a global centre of expertise in chemistry, to serve Merck & Co., Inc.’s organic and synthetic chemistry needs
x The pharmaceutical manufacturing and supply centre in Cramlington, Northumberland, continues to lead the industry and the Merck & Co., Inc. organisation in productivity, delivering important medicines to the Merck network
x There are additional administrative offices in both London and Stockley Park
x MSD has played a key role in the development of five of Merck & Co., Inc.’s products 16 medicines are manufactured in the UK by MSD
x The UK turnover in 2007 was £382 million
x The UK Sales Force is made up of around 500 field-based employees
MSD’s mission is to provide superior medicines which enhance patients’ quality of life. Of Merck & Co., Inc.’s most popular medicines, five have been discovered and 16 are manufactured by MSD in the UK.
MSD’s product portfolio covers a range of key therapy areas including atherosclerosis and cardiovascular disease, diabetes, infectious diseases, neuroscience and ophthalmology, respiratory, bone, arthritic conditions, and vaccines.
You were previously managing the Merck/Schering-Plough joint venture in the US, and arrived in the UK 2 years ago. What did you set out for yourself as head of the…
Can you provide us with an overview of what the UK market represents for the greater Lonza group? Lonza Biologics is a contract manufacturing organisation employing approximately 650 people in…
Having worked in the pharmaceutical industry for the past three decades, what attracted you to Martindale Pharma in October 2010 and what plans do you have for the company? When…
As the head of Eisai’s European operations, how would you assess the relevance of the European market for Eisai’s global operations when compared to the US or emerging markets? Gary…
Following the acquisition of Arrow Generics by Watson in December 2009, what complementarities and synergies were generated from the transaction and where do you stand today with the integration? Since…
As a partner at Apposite since the company was created in 2006, what was the founding vision of the company and what do you consider have been its major milestones…
Apitope’s research and success is based on its High Speed Technology Platform that uses soluble peptides as vehicles to regulate immune responses in patients. What is the history behind this…
As the global economic roller coaster continues to unfold, governments the world over have desperately been scrambling to find the right policies that will effectively clamp on the brakes to…
Given the global trend of clinical research increasingly being outsourced to emerging markets, such as Asia and Latin America, where does this leave historical hubs of clinical research such as…
What does the life sciences sector represent for the Scottish economy in terms of value and employment and how have these figures evolved over the last few years? The Scottish…
Within the global trend of increased economic pressures on the pharmaceutical industry, there has been a recent focus on growth in emerging markets. In this context, where does this leave…
Prior to your current position you served in a number of marketing and managerial roles including at Bayer and Sanofi-Synthelabo. What drove you to move from those larger generalized multinational…
Shire’s International Marketing to being COO of start-up medical device company, Medicsight. What about Ferring and your current role attracted you to take this job and what are you bringing…
See our Cookie Privacy Policy Here